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ABSTRACT
Background: Although a number of studies have reported the recurrence risk of 
NTDs in developed countries, there is little data on the rate of recurrence of NTDs in 
northern China, a region of high prevalence of NTDs.
Methods: Based on the population-based birth defects surveillance system of 
five counties, we identified women who had an NTD affected pregnancy from 2004-
2015 and a retrospective survey was conducted. The rate of recurrence of NTDs was 
calculated by the number of recurrent NTDs divided by the first NTDs. Maternal age, 
body mass index (BMI), gestational weeks, education, and occupation were collected. 
Information on folic acid (FA) supplements, time and dosage were also recorded.
Results: Among 851 women who had a previous NTD-affected pregnancy, there 
were 578 subsequent pregnancies, with 10 recurrent NTDs, a 1.7% recurrence rate. 
The recurrence rate was 1.5% and 2.6% for those taking FA supplements and without 
FA supplementation respectively. Women with recurrent NTDs had higher BMI before 
pregnancy compared to those who had a second pregnancy without NTDs. Among the 
recurrent NTDs, the majority were spina bifida.
Conclusions: The recurrence rate of NTDs was approximately five times higher 
than the overall prevalence in the same region of northern China. Risk of recurrence 
appeared lower among women who took FA supplements. These findings are 
consistent with the reduction in NTD frequency in the population since introduction 
of the nationwide FA supplement program. Data on recurrence rates in northern China 
will inform power calculations for future intervention studies.
INTRODUCTION
Neural tube defects (NTDs), such as anencephaly 
and spina bifida are common and severe malformations 
of the developing central nervous system. Women who 
have had a pregnancy affected by an NTD have an 
elevated risk of a subsequent NTD-affected pregnancy 
[1]. Several studies report the recurrence risk of NTDs 
in developed countries [2-4]. The recurrence rate was 
3.0% (95% confidence limits: 2.0-4.3%) in the United 
States in the late 1970s [5], 2.9% in Belgium [4] and 
1.2-1.7% in England [2, 3]. However, these studies have 
limited sample size, typically less than around one or 
two hundred [2-4], with only one study including around 
1000 cases [6].
The prevalence of NTDs in China is among the 
highest worldwide [7], but studies reporting prevalence 
have not categorized the risk of occurrence and recurrence 
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[8-10]. For example, the prevalence of total NTDs was 
1.2% in 2004 and 0.79% in 2009, declining to 0.32% 
in 2014 [10]. Hence, prevalence is approximately 10 
times higher than rates in the USA and Europe [11, 12]. 
Only one study reported an estimate of recurrence risk 
of NTDs, based on a retrospective survey in the early 
1990s. The overall recurrence was 6.9%, with differing 
rates in low, average and high prevalence areas of 3.7%, 
4.5% and 8.3%, respectively [13]. Because the recurrence 
rate of NTDs was related to the incidence of NTDs in the 
general population [5, 14], and the prevalence of NTDs 
has declined dramatically in recent years, the recurrence 
risk of NTDs may be quite different from two decades 
ago, in particular since the introduction of a folic acid 
supplementation programme.
Maternal supplementation with folic acid (FA) in the 
periconceptional period significantly reduces the risk of 
NTDs, both occurrent and recurrent [6, 15-17]. A meta-
analysis of the randomized trials indicated a 69%-87% 
reduction with use of FA for the prevention of recurrent 
NTDs and a 85–100% reduction in observational studies 
[1]. However, some of those studies were conducted 
prior to the widespread use of folic acid supplements 
and fortification of enriched cereal grain products [5], 
and some compared a specific vitamin supplement, for 
example, Pregnavite Forte F [2]. The prevention effect of 
population-based supplementation of folic acid has not 
been studied in Chinese people.
Using a population-based birth-defect surveillance 
system and a retrospective survey, the current study aimed 
to examine the recurrence of NTDs in 5 counties of Shanxi 
province, China, and to gain information on the impact 
of the FA supplement program since 2009. The study 
addressed three main issues, with the major aim being 
to determine the risk of NTD recurrence in a population 
with a high prevalence of NTDs. Our second aim was to 
evaluate, in a population with a first affected pregnancy, 
the use of FA supplements in a subsequent pregnancy, to 
determine whether FA supplementation had any protective 
effects. The third aim was to obtain information on the 
dietary characteristics of women who suffer recurrent 
NTDs.
RESULTS
In all, 1547 NTD cases were identified from 2004 
to 2015 in the five counties, and 851 cases were followed 
up in this survey, a follow-up rate of 55%. There were 
no apparent significant differences between mothers who 
participated in the follow-up study and cases in which the 
mother did not participate. There were 578 subsequent 
pregnancies following 851 first NTDs, with 10 recurrent 
NTDs, corresponding to an overall recurrence rate of 1.7% 
(10/578). The recurrence rate was 1.5% (7/456) in those 
taking FA supplements and 2.6% (3/117) in those who 
were not taking such supplements ( P=0.434).
There were no significant differences in age, 
occupation, or education between women with recurrent 
NTD pregnancies and those with unaffected pregnancies. 
However, women who suffered a recurrent NTD had 
a higher BMI before pregnancy than those who did not 
(P<0.05) (Table 1).
The proportion of women who took FA supplements 
in their second pregnancy was lower among women who 
Table 1: Characteristics of the subjects [M (SD) or n (%)]
Characteristics Women with first 
NTDs (N=851)












Age 28.0(5.6) 26.5(4.8) 26.4(4.6) 26.5(4.8) 0.955
BMI 23.5(3.3) 23.4(3.2) 27.5(5.2) 23.3(3.2) <0.001
Gestational weeks 25.3(8.0) 24.7(7.5) 22.1(4.5) 39.2(3.5) <0.001
Occupation Farmers 636(74.7) 423(73.2) 8(80.0) 415(73.1) 0.855
Others 205(24.1) 148(25.6) 2(20.0) 146(25.7)
Missing 10(1.2) 7(1.2) 0 7(1.2)
Education Primary school 104(12.2) 60(10.4) 2(20.0) 58(10.2) 0.754
Junior high school 613(72.0) 423(73.2) 7(70.0) 416(73.2)
Senior high school 
and above
126(14.8) 92(15.9) 1(10.0) 91(16.0)
Missing 8(0.9) 3(0.5) 0 3(0.5)
* Compared between recurrent NTDs and the second pregnancy without NTDs
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suffered recurrent NTDs than those who did not (P<0.05) 
(Table 2). Among the first NTD pregnancies, 73% of 
women reported taking FA supplements after they knew 
they were pregnant which was too late to prevent NTDs. In 
a recurrent NTD, 30% of women took FA after pregnancy 
(Table 3). The majority of women in each group took FA 
at a dose of 0.4 mg per day and only one individual took 
more than 5 mg per day.
The majority of first NTDs were anencephaly or 
spina bifida, which accounted for 80% of all NTDs. The 
types of NTDs affecting successive pregnancies for each 
mother were not necessarily the same in each case. Three 
pregnancies affected by anencephaly were followed by 
spina bifida in the second pregnancy, two spina bifida-
affected pregnancies were followed by anencephaly, and 
one anencephaly was followed by an encephalocele (Table 
4). Male and female babies were both represented among 
recurrent NTDs. In addition to NTDs, a number of other 
malformations or abnormal post-natal outcomes were also 
reported among women who had previously suffered an 
NTD-affected pregnancy (Table 4).
The average interval between NTD pregnancies 
in our sample was 44.5 ± 32.0 months. The shortest 
interval was 9 months and the longest was 9 years, with 
40% of second pregnancies occurring within 2 years of 
the first pregnancy and 60% occurring after 2 years or 
more (Table 5). There were no significant differences in 
reported dietary frequency except for tea consumption 
(Supplementary Table 1) between women who had a 
recurrent NTD and those who did not.
DISCUSSION
We investigated the recurrence rate of NTDs in a 
region of historically high prevalence of NTDs in China. 
Among 578 pregnancies following a previous NTD-
affected pregnancy, the total recurrence risk was 1.7%. 
Among recurrent NTDs, the prevalence among women 
who did not take folic acid supplements was almost double 
that of those who take folic acid supplements (2.6% vs 
1.5%). The prevalence of NTDs in the study area was 
0.32% in 2014, which was approximately ten times higher 
than in the USA [10] and 2.5 times higher than another 
northern province Liaoning (0.13%) [18] at same time. 
The rate of recurrent NTDs was 5 times higher than the 
prevalence of NTDs in the same area of China.
The recurrence rate in our study was similar to that 
reported in England, 1.2-1.7% in early 1990s [3, 2], and 
was much lower than the previously reported recurrence 
risk of NTDs in China in the early 1990s [13]. This 
difference in recurrence rate occurred in parallel with a 
reduction in the overall prevalence of NTDs which may be 
Table 2: Characteristics of NTDs in first and recurrent pregnancy [n(%)]










Anencephaly 379(44.5) 3(0.5) 3(30.0)
Spina bifida 398(46.8) 6(1.0) 6(60.0)
Encephalocele 74(8) 1(0.2) 1(10.0)
Other type 19(3.3) 0
No BD 542(93.8)
Male 383(45.0) 309(53.5) 5(50.0) 304(53.5) <0.001
Sex Female 372(43.7) 258(44.6) 3(30.0) 255(44.9)
Bisexual 1(0.1) 0
Unknown 95(11.2) 11(1.9) 2(20.0) 9(1.6)
FA supplements
Yes 233(27.4) 455(78.7) 7(70.0) 449(79.0) 0.012
No 586(68.9) 117(20.2) 3(30.0) 114(20.1)
Missing 32(3.8) 6(1.0) 5(0.9)
FA supplements before 
pregnancy
Yes 63(7.4) 276(47.8) 3(30.0) 273(48.1)*
*Compared between recurrent NTDs and the second pregnancy without NTDs
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attributable to the nationwide folic acid supplementation 
program initiated in 2009. The same trend was found in 
Liaoning [18]. The program provides free folic acid tablets 
to all women who have a rural registration and who plan to 
become pregnant [10, 19, 20].
Clinical trials and the outcome of fortification 
campaigns show that folic acid supplementation can 
prevent first occurrence of NTDs and recurrent NTDs. 
Our study suggests that a lower proportion of women with 
recurrent NTDs took FA supplements than women who 
did not have a recurrent NTDs. Among women who had a 
previous affected pregnancy, less than 50% took FA in the 
period before their next pregnancy, suggesting that health 
education initiatives should emphasize the optimal period 
of supplementation as well as dosage of FA supplement 
that is protective. As formation of the neural tube occurs 
during weeks 3-4 of pregnancy, it is too late for women 
to take folic acid after they know they are pregnant. To 
obtain optimal blood folate levels to prevent NTDs, it 
recommended to supplement FA in the periconceptional 
period (28 days before through 28 days after the last 
menstrual period) [21]. Moreover, to prevent NTD 
recurrence, a dose of 4-5 mg FA per day is recommended, 
as compared with 0.4 mg, based on the findings of the 
MRC Vitamin study in which the risk of recurrent NTDs 
was reduced by 72% [6].
Although folic acid supplementation may not be 
able to prevent all NTDs, it is clear that it has a protective 
effect. NTDs still arise in regions that have mandated 
FA fortification of enriched cereal grain products. For 
example, the rate of NTDs in South Carolina, USA, 
remained at 0.66 NTDs per 1,000 live births and 
fetal deaths after 20 years of extensive promotion of 
periconceptional FA use and 14 years of fortification 
of cereal grain flour [23]. In contrast to the food 
fortification approach of the USA and other countries, 
China implemented a public health campaign to provide 
FA tablets (0.4 mg per day) to women who may become 
pregnant. Although the tablets are provided free of charge, 
the compliance is not satisfactory; our previous study 
showed that the percentage of FA supplementation before 
the last menstrual period is around 40% [20]. Folic acid 
fortification of staple foods could be recommended to 
further prevent NTDs in China [10].
Our study found that the BMI of women who had 
a second NTD-affected pregnancy was higher than that 
of women who did not. It is possible that this contributed 
to NTD risk, as a higher BMI has been found to be an 
independent risk factor for NTDs [24, 25]. A population-
based case-control study revealed that pre-pregnancy 
maternal overweight/obese women were more likely than 
average-weight women to have an infant with spina bifida, 
heart defects and multiple anomalies [25]. A meta-analysis 
reported that the odds ratio of NTDs in offspring was 1.04 
(95% CI 1.027–1.051) for every 1 kg/m2 BMI increase in 
mothers, and indicated that maternal obesity is an important 
risk factor for NTDs in offspring [24]. Maternal obesity is a 
risk factor for adverse pregnancy outcome, suggesting that 
obesity prevention efforts are needed to increase the number 
of women who are of healthy weight before pregnancy.
Table 3: Description of folic acid supplement for the first and second pregnancy (among those taking folic acid)
Folic acid (FA) 
supplement







Period of FA supplementation 0.770
3 months before 
pregnancy
31(13.3) 218(37.7) 3(43.0) 215(37.9)
2 months before 
pregnancy
7(3.0) 27(4.7) 0 27(4.8)
1 month before 
pregnancy
25(10.7) 31(5.4) 0 31(5.5)
After pregnancy 170(73.0) 179(31.0) 4(57.0) 175(30.8)
Missing 0 123(21.3) 0 120(21.1)
FA supplements dose 0.722
0.4 mg 331(57.3) 4(57.0) 327(57.6)
0.8 mg 36(6.2) 1(14.0) 35(6.2)
1-3 mg 6(1.0) 0 6(1.1)
≥4 mg 69(11.9) 1(14.0) 68(12.0)
Missing 136(23.5) 1(14.0) 132(23.2)
*Compared between recurrent NTDs and the second pregnancy without NTDs
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Our study had several strengths. First, it was based 
on a population-based surveillance system, and the 
surveillance covered 95.6% of births [7], which ensures 
quality data. Second, the NTDs were double checked by 
local doctors and pediatricians from Peking University, 
which ensures the accuracy of diagnosis. However, several 
limitations prohibited further analysis. One limitation of 
the present study was that it may have underestimated 
the recurrent risk of NTDs because almost half of the 
participants were not followed up. The second limitation 
was that it included only five counties, and the results may 
not be generalizable to the entire province or country. The 
third limitation was that few risk factors were evaluated, 
which hindered our ability to explore the risk factors for 
recurrent NTDs. Future studies should use a larger sample 
size and collect more information.
In conclusion, the prevalence of recurrent NTDs 
remains high in the research area, although implementation 
of the FA supplementation program has been associated 
with lower overall prevalence of NTDs. Improving the 
Table 4: Characteristics of two pregnancies with birth defects by types [n(%)]
First pregnancy Second pregnancy Frequency
Anencephaly Spina bifida 3
Anencephaly Cleft palate 1
Anencephaly Encephalocele 1
Anencephaly Miscarriage 1
Anencephaly Cardiac defect 1
Anencephaly Embryo arrest 1
Anencephaly Autism 1
Anencephaly Others BD, but don’t know the type 2
Spina bifida Spina bifida 3
Spina bifida Anencephaly 3
Spina bifida Cerebral palsy 2
Spina bifida Embryo arrest 2
Spina bifida Hypospadias 1
Spina bifida Others BD, but don’t know the type 5
Encephalocele Ear malformation 1
Table 5: Interval between two pregnancies with NTDs
Case number First pregnancy Second pregnancy Interval(month)
1 Anencephaly Encephalocele 46
2 Anencephaly Spina bifida 108
3 Spina bifida Spina bifida 19
4 Spina bifida Spina bifida 42
5 Spina bifida Spina bifida 9
6 Anencephaly Spina bifida 18
7 Anencephaly Spina bifida 71
8 Spina bifida Anencephaly 31
9 Spina bifida Anencephaly 79
10 Spina bifida Anencephaly 22
Mean (SD) 44.5(32.0)
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compliance of FA supplementation as a public health 
campaign could lead to further reduction of the prevalence 
of NTDs. Some recurrent NTDs arose despite the use of FA 
supplements, suggesting that further investigations of other 
NTD risk factors and/or preventive measures are warranted.
MATERIALS AND METHODS
Subjects
The study was based on the population-based birth 
defects surveillance system of five counties (Pingding, 
Xiyang, Taigu, Zezhou and Shouyang) in northern China 
[7, 10].
Followed the model of a public health campaign 
which was to evaluate the effect periconceptional folic acid 
supplementation to prevent NTDs [26], the surveillance 
system covers more than 20,000 births in the above five 
counties each year. Any infant suspected of having a 
major structural external birth defect by prenatal diagnosis 
or at delivery is reported by local health care providers. 
Information of preliminary diagnosis of birth defects and 
basic demographic information, including birth date, sex, 
birth order and a detailed clinical description (including 
measurements where applicable) of the birth defect(s) were 
collected and a photograph of affected infants was taken 
within the first 24 h after delivery. Definitive diagnosis, 
classification and coding of structural birth defects were 
conducted by a clinical geneticist from Peking University. 
These data can be used for descriptive epidemiology of birth 
defects [26]. Details of the surveillance system are available 
elsewhere [10]. Briefly, all live births (births of 28 or more 
complete gestational weeks), all stillbirths of at least 20 weeks 
gestational age, and pregnancy terminations at any gestational 
age following the prenatal diagnosis of NTDs were included. 
We identified women who had an NTD-affected pregnancy in 
the period 2004–2015, and conducted a retrospective survey. 
We hypothesized that the NTD identified in the surveillance 
system was the first NTD pregnancy for the woman. If 
women appeared in the surveillance system a second time 
or more, we checked the date of the end of the pregnancy 
to determine which was the first NTD and then further 
pregnancies were identified as recurrent NTD pregnancies. 
NTDs included anencephaly (International Classification of 
Diseases, Tenth Revision, Clinical Modification, ICD-10-
CM: 740.0), spina bifida (741.90), and encephalocele (742.0). 
A structured interview was administrated by a local health 
care provider, including the birth information of NTDs and 
recurrent NTDs, and dietary frequency and life style factors. 
The dietary frequency has been used in our previous study 
[27] and included the frequency of taking meat, sea food, 
eggs, milk, fresh vegetables, fresh fruits, legume and local 
pickled vegetable per week; life style factors included the 
frequency of tea drinking and passive smoking. An annual 
work meeting was held for staff who collected and reported 
data of surveillance system of every county, and the staffs 
were trained every year. The study protocol was reviewed 
and approved by the Institutional Review Board of Peking 
University.
Statistical analysis
NTDs were classified as “recurrent” if they affected 
the pregnancy of a mother with a prior NTD-affected 
pregnancy. NTDs included three major subtypes, namely, 
anencephaly, spina bifida, and encephalocele.
The prevalence of recurrent NTDs was calculated 
as the number of recurrent NTDs divided by the number 
of occurrent NTDs. Data on maternal age, body mass 
index (BMI) of women before the pregnancy, gestational 
weeks, education, and the occupation at the time the first 
NTDs occurred were collected, as were details about 
NTD types, sex, interval between the two NTDs, FA 
supplementation, and duration and dosage of FA. Dietary 
information was compared between affected women and 
controls. Statistical analyses were conducted using a t-test 
for comparison of maternal age, BMI, gestational weeks in 
groups; a Chi-square test were used for comparison of the 
categorical data, including maternal education, occupation, 
sex of offspring, FA supplementation information, et al. A 
two-tailed P ≤ 0.05 was considered statistically significant. 
All statistical analyses were performed using the SPSS 
package version 20.0 (SPSS Inc.).
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